Endocrinology · Coral Springs, FL
NPI
1013020072
Since 2006
Specialty
Endocrinology
Code 174400000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
1505 N University Dr, Suite 300
Coral Springs, FL, 33071
Phone (954) 575-4040
Groups this clinician bills Medicare through
Medicare paid, 2024
$37K
365 services
Medicare patients, 2024
178
Average age 74
Drug cost, 2024
$1.9M
3,976 prescriptions
Company payments, 2025
$1,257
From 15 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Vivian P Rose was code 99214 (office e&m - established), 295 times for 151 patients. In total Vivian P Rose billed 365 services in 5 codes, and Medicare paid $37K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-05-20.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 295 | 151 | $96.40 | $28K |
| 99215 Office E&M - Established | Office | 26 | 21 | $142.16 | $3,696 |
| 99204 Office E&M - New | Office | 19 | 19 | $135.25 | $2,570 |
| 99213 Office E&M - Established | Office | 16 | 14 | $72.97 | $1,167 |
By year: 2022 $55K for 555 services; 2023 $50K for 493 services; 2024 $37K for 365 services.
Medicare prescription drug claims, 2024
In 2024, the drug Vivian P Rose prescribed most often to Medicare patients was Glipizide, with 526 prescriptions and refills. In total Vivian P Rose wrote 3,976 Medicare prescriptions that cost $1.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Glipizide Generic | 526 | 1,472 | 185 | $6,265 |
| Levothyroxine Sodium Generic | 369 | 1,012 | 122 | $3,748 |
| Synthroid Levothyroxine Sodium | 340 | 770 | 89 | $35K |
| Jardiance Empagliflozin | 278 | 520 | 80 | $299K |
| Pioglitazone Hcl Generic | 212 | 563 | 75 | $2,228 |
| Ozempic Semaglutide | 208 | 356 | 50 | $345K |
| Unithroid Levothyroxine Sodium | 156 | 380 | 47 | $19K |
| Metformin Hcl Generic | 153 | 434 | 56 | $1,028 |
| Mounjaro Tirzepatide | 129 | 178 | 26 | $188K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 93 | 234 | 44 | $6,896 |
| Trulicity Dulaglutide | 90 | 122 | 21 | $117K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 79 | 156 | 25 | $12K |
| Soliqua 100-33 Insulin Glargine/Lixisenatide | 79 | 121 | 18 | $79K |
| Farxiga Dapagliflozin Propanediol | 79 | 125 | 16 | $69K |
| Rybelsus Semaglutide | 75 | 150 | 32 | $139K |
Brand drugs: 2,212 claims; generic drugs: 1,511 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Vivian P Rose $1,257 ($1,257 in general payments such as food, travel and fees) from 15 companies. The largest payer was Amneal Pharmaceuticals LLC with $192.
| Company | Payments | Amount |
|---|---|---|
| Amneal Pharmaceuticals LLC AMRX | 12 | $192 |
| Novo Nordisk Inc NVO | 9 | $163 |
| Abbvie Inc. ABBV | 11 | $159 |
| Insulet Corporation PODD | 6 | $147 |
| Lilly USA, LLC LLY | 6 | $114 |
| Amgen Inc. AMGN | 4 | $83.67 |
| Neurocrine BioSciences, Inc. NBIX | 3 | $75.11 |
| Corcept Therapeutics CORT | 4 | $73.49 |
| Xeris Pharmaceuticals, Inc. | 3 | $62.42 |
| Recordati_rare_diseases_inc. | 3 | $55.93 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.